ClinicalTrials.gg

Generalized Anxiety Disorder clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 518 studies for Generalized Anxiety Disorder across more than 10 countries. 125 are recruiting or about to start. 315 of them are mainly about Generalized Anxiety Disorder (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 753 studies for Generalized Anxiety Disorder. How that becomes 517 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Generalized Anxiety Disorder, and those it files under no condition that list Generalized Anxiety Disorderthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 753Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1List Generalized Anxiety Disorder as a condition, but the registry did not file them under itMost often written as “Analogue Generalized Anxiety Disorder” (1). The registry filed them under other conditions only, most often Anxiety Disorders (1).
  3. −235Match it another way42 name it in the title, 7 in a keyword, and 186 by a synonym or other text the search reads.
  4. 517The count on this page2 of them list Generalized Anxiety Disorder in their own words; the registry filed them under no condition.

Status

Completed
293
Recruiting
87
Not yet recruiting
33
Status unknown
31
Terminated
29
Active, not recruiting
27

Phase

Phase 3
70
Phase 2
50
Phase 4
40
Phase 1
22
Early Phase 1
1

Where

United States
265
Canada
50
Sweden
23
China
23
United Kingdom
15
France
12

Who develops what

Add Generalized Anxiety Disorder to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 7 companies, 7 with this as their studies’ main aim; 4 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Otsuka, AbbVie and Johnson & Johnson here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Conventional TherapyRecent, limited
Evidence
  • NCT07477990 · psicofarma s a de c v · Phase 3 · live · comparator · “Pharmacological conventional treatment” · registered Nov 2025
—11 study
LorazepamEarlier only
Evidence
  • NCT00807937 · AstraZeneca · Phase 2 · comparator · “Lorazepam” · registered Dec 2008
  • NCT00624780 · Viatris Inc. · Phase 4 · comparator · “Lorazepam” · registered Feb 2008
Pfizer30% of its industry studiesUS: off-patent, 14 generics marketed00 studies
EscitalopramEarlier only
Evidence
  • NCT00481325 · Bristol-Myers Squibb · Phase 3 · comparator · “escitalopram” · registered May 2007
  • NCT00417118 · Sanofi · Phase 3 · comparator · “Escitalopram” · registered Dec 2006
AbbVie19% of its industry studiesUS: off-patent, 16 generics marketed00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ulotaront☆ Track3 live phase-3 studies: NCT07759128, NCT07767903, NCT07786454Otsuka Holdings Co., Ltd.
deulumateperone☆ Track2 live phase-3 studies: NCT07807865, NCT07856420Johnson & Johnson
lysergide D-tartrate☆ Track2 live phase-3 studies: NCT06741228, NCT06809595Definium Therapeutics US, Inc.
buagafuran☆ Track2 live phase-3 studies: NCT06243640, NCT06243614Beijing Union Pharmaceutical Factory Ltd

The 4 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.ABBV-932 · AbbVie · Phase 2 main aimNCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder — primary endpoint: Number of Participants with Adverse Events (AEs) · 315 enrolled
  • Jan 2027 est.SYT-510 · Synendos Therapeutics AG · Phase 2 main aimNCT07478744 A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder — primary endpoint: BOLD fMRI signal in the amygdala in response to fearful stimuli · 24 enrolled
  • 16 Mar 2027 est.deulumateperone · Johnson & Johnson · Phase 2 main aimNCT06480383 Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder — primary endpoint: Hamilton Anxiety Rating Scale (HAM-A) · 705 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Generalized Anxiety Disorder studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Serotonin receptor agonists 2 open · Psychedelics 1 open · Antipsychotics 20 · SSRIs 18 · SNRIs 8

Coming up

43studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 87 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 53 (61%) stop at 75 or younger. 15 (17%) take children under 18. 2 (2%) are for women only and 0 (0%) for men only; 16 (18%) take healthy volunteers.

Recruiting studies that take each age, of 87
AgeWomenMen
108 (9%)8 (9%)
1879 (91%)77 (89%)
3075 (86%)73 (84%)
4072 (83%)70 (80%)
5070 (80%)68 (78%)
6563 (72%)61 (70%)
7535 (40%)34 (39%)
8532 (37%)31 (36%)

Across all 518 studies, recruiting or not: 63% stop at 75 or younger and 56% at 65; 17% take children; 3% are for women only and <1% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Generalized Anxiety Disorder studies take

Of 184 interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase28 mo15–52 · 184 studies—29 mo16–53 · 175 studies
Observational17 mo9–56 · 24 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 518. Browse all 518 → or search them.